The U.S. Food and Drug Administration has approved a new medication called Tyvaso for two serious lung conditions. Tyvaso is an inhaled drug that treats two types of high blood pressure in the lungs: pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. These conditions make it hard for the heart to pump blood through the lungs, causing shortness of breath and limiting physical activity.
Tyvaso is specifically for adults with these conditions who need help improving their ability to exercise and do daily activities. The drug is taken using a specialized inhaler system four times a day. This approval means doctors now have another treatment option to offer patients who struggle with these challenging conditions.
It's important to understand that while this approval is good news, the clinical studies for pulmonary arterial hypertension lasted only 12 weeks and most patients were already taking other medications. The effects of Tyvaso wear off between doses, so timing of treatments can be adjusted around planned activities.
If you or someone you know has one of these conditions, the most important step is to have a conversation with your healthcare provider. They can explain whether Tyvaso might be appropriate based on your specific situation and medical history.